Boehringer Ingelheim agreed to acquire global rights to a preclinical antibody program from Immunitas Therapeutics, adding a chronic inflammatory and autoimmune asset to its immunology pipeline. Financial terms include an undisclosed upfront payment plus eligibility for up to $478 million across development, regulatory, and commercial milestones. Immunitas’ program is designed to selectively eliminate pathogenic cells at inflammation sites rather than simply suppressing signaling intermediates. Boehringer will take responsibility for worldwide development, manufacturing, and commercialization, positioning the antibody as a potential option for patients who do not respond to existing therapies. Immunitas said the partnership enables clinical progression with Boehringer’s global development capabilities in immunology and drug development. The deal reflects continued pharma demand for differentiated immunology modalities that combine tissue targeting with longer disease control rather than broad immune suppression alone.